




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CPRIT University Advisory Committee: 2025 Annual Report

CPRIT Oversight Committee Meeting

May 21, 2025

Subhash C. Chauhan, Ph.D., Vice Chair



Carlos L. Arteaga, M.D.
Chair 2023- 2025
The University of Texas Southwestern Medical Center

Subhash C. Chauhan, Ph.D.
Vice Chair, 2023- 2025
The University of Texas Rio Grande Valley

Abbey B. Berenson, M.D., MMS, Ph.D.
The University of Texas Medical Branch at Galveston

Deborah Clegg, Ph.D.
Texas Tech University Health Sciences Center, El Paso

Peter Davies, M.D., Ph.D.
Texas A&M Health Science Center

Giulio F. Draetta, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center

Joseph “Joe” Heppert, Ph.D.
Texas Tech University

Shreek Mandayam, Ph.D.
Texas State University


Claudia Neuhauser, Ph.D.
University of Houston/University of Houston System

Ramamoorthy Ramesh, Ph.D.
Rice University

Pavan Reddy, M.D.
Baylor College of Medicine

UAC Membership - broad representation

- Institutional Representatives- senior administrative leaders, Cancer Center Directors
- Health-related Institutions and Academic Campuses
- Active researchers – CPRIT Scholars and funded investigators
- Regional representation



UAC Meetings – 2024/2025

April 4, 2024

- Discussed Recruitment FY25.1 RFAs in relation to budget allocation and number of cycles
- Discussed posted FY25.1 RFA Mechanisms
- Discussed potential FY25.2 RFA Mechanisms

February 27, 2025

- Discussed Recruitment FY26.1 RFAs in relation to budget allocation and number of cycles
- Discussed posted FY26.1 RFA Mechanisms
- Discussed potential FY26.2 RFA Mechanisms
- Discussed a Summary of Fiscal Year 2024 Academic Research Awards

Focus of Discussion

- Recruitment Program
- Individual Investigator Research Awards (IIRA) Program
- Return on Investment (ROI) for funding mechanisms



Table 1: FY25 Academic Research Program Data Funding Information

Cycle	Mechanism	No. of Applications Submitted	Total Funding Requested	# Applications Recommended by SRC	Total Funding Recommended by SRC	Success Rate
25.1	Individual Investigator Research Awards (IIRA)	220	\$196,400,895	28	\$25,183,459	13%
	IIRA for Children and Adolescents	36	\$42,160,677	6	\$7,162,997	17%
	IIRA for Clinical Trials	26	\$41,025,711	3	\$4,588,613	11%
	IIRA for Computational & Systems Biology	29	\$29,883,203	3	\$2,862,063	10%
	IIRA for Early Onset of Cancer	13	\$11,379,861	0	\$0	N/A
	IIRA for Prevention and Early Detection	21	\$24,022,601	5	\$5,956,505	24%
	CAP: CAC	1	\$3,000,000	1	\$3,000,000	N/A
	Core Facility Support Award (FY2024)	1	\$2,999,989	1	\$2,999,989	N/A
25.1	IIRA Totals	346	\$350,872,937	47	\$51,753,626	13%
25.2	Core Facility Support Awards	19	\$52,693,483	11	\$29,149,186	57%
	High Impact/High Risk Awards	96	\$23,987,428	17	\$4,249,306	18%
	Early Clinical Investigators	7	\$6,888,202	3	\$2,999,495	43%
	TREC: AIIRA	18	\$13,498,858	1	\$750,000	6%
	TREC PSA	14	\$2,255,701	3	\$600,000	21%
	TREC CFSA	6	\$11,980,341	1	\$2,000,000	16%
		160	\$111,808,013	36	\$39,747,987	23%
	FY25 Aggregate Totals	506	\$462,680,950	83	\$91,501,613	16%

Table 2: FY25.1 Recruitment Data and Funding Information

Mechanism	No. of Applications Submitted	Total Funding Requested	Applications Recommended by SRC	Total Funding Recommended by SRC	Success Rate
Recruitment of Established Investigators	9	\$54,000,000	5	\$30,000,000	56%
Recruitment of Rising Stars	14	\$42,594,367	1	\$4,000,000	7%
Recruitment of First-Time, Tenure-Track Faculty Member	45	\$100,246,984	24	\$48,000,000	53%
Total	68	\$201,841,351	30	\$82,000,000	44%



Table 3: Research IIRA RFAs by Mechanism, Award Funding, and Metrics

RFA	No. of Awards	Award Funding (Million)	Follow-On Funds (Million)	Patents Filed	Pubs	No. of Clinical Trials	No. of Patients Enrolled
Individual Investigator Research Awards (IIRA)*	528	\$496	\$489	88	1806	36	4,576
IIRA for Children and Adolescents	61	\$81	\$40	9	174	11	5,465
IIRA for Clinical Translation/Clinical Trials	17	\$32	\$1.7	0	71	17	1,774
IIRA for Computational Systems Biology	17	\$17	\$2	5	117	0	0
IIRA for Prevention and Early Detection	36	\$49	\$16	4	124	18	15,116
Total	659	\$675	\$549	106 Filed/29 Granted	2292	82	26,931

* IIRAs initiated in 2010; the four targeted IIRAs were initiated between 2015-2018

Table 4: Research RFAs by Mechanism, Award Funding, and Key Metrics

RFA	No. of Awards	Award Funding (Million)	Follow-On Funds (Million)	Patents Filed	Pubs	No. of Clinical Trials	No. of Patients Enrolled
Core Facility	83	\$328	\$1,600	50	1952	46	7803
High-Impact, High Risk	235	\$50	\$80	44	413	7	819
Multi-Investigator	41	\$211	\$307	33	1279	31	12,502
Total	359	\$589	\$1,987B	127 Filed/26 Granted	3644	84	21,124

Source: Annual Progress Reports, Self-Reported Data by Scholars (4/14/2025)



**Table 5: Texas Regional Excellence in Cancer (TREC):
Research RFAs by Mechanism, Award Funding, and Key Metrics**

RFA	No. of Awards	Award Funding	Follow-On Funds	Patents Filed	Pubs
TREC Awards (2021 - 2; 2023 - 3)	5	\$29,888,000	\$16,240,371	2 filed 2 granted	63
TREC Major Instrumentation Award (3 in 2023)	3	\$2,890,000	\$1,589,814	0	1
TREC Pilot Study Award (5 in 2023)	5	\$5,000,000	0	1 filed	1
TREC Institutional Postdoctoral Training Awards (1 in 2023)	1	\$850,000	N/A	N/A	N/A
Total	14	\$38,628,000	\$17,830,185	3 Filed/2 granted	65



Table 6: Recruitment of Scholars by Mechanism, Award Funding, and Metrics


RFA	Accepted	Award Funding (Million)	Follow-On Funds (Million)	Patents Filed	Pubs	No. of Clinical Trials	No. of Patients Enrolled
Established Investigator	67	\$398	\$520	215	1329	43	5599
Rising Star	34	\$126	\$152	4	508	18	1969
First-Time, Tenure Track	230	\$456	\$543	58	1460	11	1902
Total	334	\$980	\$1.2B	277 Filed/13 Granted	3297	72	9470

Source: Annual Progress Reports, Self-Reported Data by Scholars



Recruitment Data by Gender and Success Rates

FY	No of Submissions		No of Recommended		Success Rate	
	Male	Female	Male	Female	Male	Female
2014	32	11	16	6	50.0%	54.5%
2015	45	15	25	9	55.6%	60.0%
2016	56	16	28	8	50.0%	50.0%
2017	50	15	28	6	56.0%	40.0%
2018	46	15	25	5	54.3%	33.3%
2019	53	33	30	17	56.6%	51.5%
2020	61	23	29	7	47.5%	30.4%
2021	37	27	24	15	64.9%	55.6%
2022	50	26	30	13	60.0%	50.0%
2023	31	10	17	5	54.8%	50.0%
2024	32	14	15	7	46.9%	50.0%
2025	47	21	19	11	40.4%	52.4%
Total	540	226	286	109	53.0%	48.2%



The Value Proposition

An Economic Assessment of the Cost of Cancer in Texas and the Benefits of CPRIT and its Programs: 2024 Update
THE PERRYMAN GROUP

Reducing the burden of cancer provides benefits to individuals, families, hospitals, state and local governments, insurance providers, and society as a whole.

Basic medical research is also a part of society's essential infrastructure, and CPRIT has demonstrated the capacity to enhance the health of Texans and the economy at a pace that far exceeds the direct investment.

Every \$1 spent through CPRIT for screening/prevention saves \$2.33 in direct health spending and leads to a total of \$29.73 in treatment cost savings and resulting economic benefits through earlier detection.

The current total annual impact of all CPRIT operations, prevention/screening, and research programs (including initial outlays and multiplier effects) includes \$672.2 million in output (real gross product) in 2024 as well as about 7,640 jobs. When all secondary and downstream benefits are considered, these values rise to more than \$27.1 billion in output and 224,575 jobs.

2025 Recommendations

- Scholar Recruitment RFAs (Reduce from 12 to 9 cycles to accommodate budget and institutional recruitment schedules)
- Focus on High-Impact Funding Mechanisms:
 - Core Facility Support RFAs
 - Clinical Trials Focused RFAs
 - Research Training RFAs
 - RFAs targeted to TREC-eligible institutions
 - RFA focusing on emergent cancers impacting Texans




Summary and Conclusions

- The Covid catastrophe provided an important opportunity to take stock of priorities and recalibrate existing programs as well as new programs to leverage the accomplishments of the last 16 years in charting a new course for the future.
- **Going forward it will be necessary to re-evaluate programs to address the evolving national research funding environment.**
- From the UAC perspective, the Academic Research Program is a remarkable accomplishment – a stable, valuable program supporting all aspects of cancer research in Texas.
- The academic research community, through the UAC, expresses its gratitude to the leadership of CPRIT for their support and the very inclusive approach they have taken to engage the opinion of key stakeholders in the research enterprise.




Background and Significance of ST-CECR

- Hispanics or Latino are the second largest racial/ethnic group in the United States after non-Hispanic whites (NHWs)
- The four-county Rio Grande Valley (RGV) region, where ~ 1.3-1.5 million people reside
- RGV Region represents with the nation's highest rates for liver, gall bladder, stomach, cervical cancers
- *A cancer research facility is urgently required to address these unacceptable cancer related health disparities in the region*



Demonstration of geographical distance between UTRGV and other major institutions



RGV Region of South Texas

ST-CECR Grant Submission/Funding

ST-CECR has submitted more than 40 proposals with a total request of ~\$90,000,000 for this FY through the end of August 2024

This includes:

- **25M NIH RCMI project (Funded 18.45 M)**
- **4.5 M CPRIT MIRA Project**
- **3.0 M CPRIT Core facility project**
- **3.0 M CPRIT Core facility project (TREC)**
- **CPRIT IIRA projects (TREC)**
- **CPRIT Pilot projects (TREC)**
- **CPRIT HHRA projects (TREC)**
- **NIH R01s**
- **NSF Career Award**
- **ST-CECR has successfully secure funding from two private foundations:**
- **Kosten Foundation (65K, 50K on pancreatic cancer)**
- **My Good Days Foundation (50K on cervical cancer prevention, likely to be continued)**
- **SSA Foundation (375K ALS and Cancer Biomarkers)**
- **H2Ocen Pilot Project (15K)**



THE NEWSROOM

Friday, October 18, 2024

[Headlines -](#)

[In the News -](#)

[About Us](#)

[Multimedia -](#)

UTRGV awarded \$18.4M NIH grant to establish cancer research center



In the front row, seated from left to right: Dr. Everardo Cobos, chair of medicine and oncology; Dr. Subhash C. Chauhan, director of the South Texas Center of Excellence in Cancer Research; Dr. Michael Hocker, dean of the UTRGV School of Medicine and senior vice president for UT Health RGV; U.S. Rep. Vicente González (TX-34); UTRGV President Guy Bailey; and Dr. Can (John) Saygin, senior vice president for research and dean of the Graduate College. Researchers from the South Texas Center of Excellence in Cancer Research stand behind them. (UTRGV photo by Jesús Alfárez)

Cancer Center Activities



ST-CECR Seminar Series



ST-CECR Conference

UTRGV | **UT Health**
Rio Grande Valley
School of Medicine

The South Texas Center of Excellence in Cancer Research and the School of Medicine Research Office would like you to

SAVE THE DATE

for the
3rd International Conference on Cancer Health Disparities at the
2025 SOM Research Symposium

FEB. 14-15

MISSION EVENT CENTER - MISSION, TX



Thank You